Eumentis Therapeutics, Inc.
Novel therapeutics for neuropsychiatric disorders
- Sector
- Biotech
- Headquarters
- NEWTON, MA
- Founded
- 2019
- Latest Form D
- $765K, Jun 2024
- Total capital
- $11.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $11.3M
- 4 Form D · last Jun 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$765K
- Private capital raisedForm D · SEC · 3rd filing$4M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Private capital raisedForm D · SEC · 1st filing$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Andrew PearlmanDirectorNamed in SEC Form D filings
- James LarrickDirectorNamed in SEC Form D filings
- Kim PatrickDirectorNamed in SEC Form D filings
- Mark TepperExecutive Officer, DirectorNamed in SEC Form D filings
- Maryann BrylaDirectorNamed in SEC Form D filings
- Randall MarshallExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingNitro-aminoadamantane Compounds For The Treatment Of Betacoronavirus InfectionsUSPTOApplication 17912611
- PendingNitro-aminoadamantane Compounds For The Treatment Of Negative Symptoms And Cognitive Impairment Associated With SchizophreniaUSPTOApplication PCTUS2021032006
- PendingNitro-aminoadamantane Compounds For The Treatment Of Betacoronavirus InfectionsUSPTOApplication PCTUS2021023092
Show all 5 patent records
- Nitro-aminoadamantane Compounds For The Treatment Of Betacoronavirus InfectionsJul 13, 2023 · Application 17912611Pending
- Nitro-aminoadamantane Compounds For The Treatment Of Negative Symptoms And Cognitive Impairment Associated With SchizophreniaApplication PCTUS2021032006Pending
- Nitro-aminoadamantane Compounds For The Treatment Of Betacoronavirus InfectionsApplication PCTUS2021023092Pending
- Nitro-aminoadamantane Compounds For The Treatment Of Negative Symptoms And Cognitive Impairment Associated With SchizophreniaApplication 63023310Pending
- Nitro-aminoadamantane Compounds For The Treatment Of Betacoronavirus InfectionsApplication 62991851Pending
Related companies, and why
- EvodiaBioSimilar federal contract value in Biotech · null in contracts
- MYCOBACTERIA THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
- NEYROBLASTGX LLCSimilar federal contract value in Biotech · null in contracts
- Perfuse Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- CANTEX PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- Swan NeuroTech, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .